


1
2

Supplementary Information




3

4 **Supplementary Figure 1: Biophysical analysis of the CD36:CIDR α 2.8 complex**

5 Analysis of the formation of a 1:1 complex of CD36 bound to the MCvar1
6 CIDR α 2.8 domain by SEC-MALLS.


7



8

9 **Supplementary Figure 2: Stereo image of electron density**


10 A stereo image of the electron density for residues 148-160 of CD36. This is
11 representative of the quality of electron density throughout the complex and
12 contains the important residue, F153, which lies at the interface with the MC179
13 CIDR α 2.8 domain.



14

15 **Supplementary Figure 3: Structural comparison of CIDR α domain structures**

16 **A.** The structure of the MCvar1 CIDR α 2.8 domain determined in this study in
 17 comparison with the previously determined 'open' conformation of the MCvar1
 18 CIDR α domain, obtained in a pH 4.2 crystallisation condition (pdb:3C64). **B.**
 19 Comparison of the MCvar1 CIDR α 2.8 structure, determined in this study with
 20 previous CIDR α 1 (pdb:4V3D) and CIDR γ (pdb:2YK0) structures reveals these to
 21 adopt a compact structure with a core three α -helical bundle and the insertion
 22 linking the second and third helices packing against the rest of the domain.



23

24 **Supplementary Figure 4: Analysis of CD36 and its homologues**



25 An alignment of the sequence of CD36 with those of its homologues SR-BI
 26 and LIMP2. Above the alignment is the secondary structure of CD36, derived from
 27 the crystal structure. Orange and pink circles show residues that interact with
 28 the two fatty acids while green squares show those that interact with the MCvar1
 29 CIDR α 2.8 domain. Orange, green and purple lines show the positions of the
 30 disulphide bonds of CD36; and dotted lines show the disulphide bonds of LIMP-
 31 2. Green hexagons show the positions of N-linked glycans on CD36 (above the
 32 sequence) and LIMP-2 (below the sequence) while the purple hexagon shows a
 33 position predicted to be glycosylated on CD36 but without a glycan.

34

35

36

37



38

39 **Supplementary Figure 5: Fatty acid identification by mass spectrometry**

40 Fatty acids were chloroform extracted from the protein used for crystallisation
41 and were converted to their corresponding trimethylsilyl esters and analysed by
42 GC/MS. Masses were consistent with the identification of the most prevalent
43 species as palmitic acid and stearic acid.

44

45


46

47

48

49

50



51

52


53 **Supplementary Figure 6: Analysis of crystal packing**

54 **A.** In crystals of CD36 bound to the MCvar1 CIDR α 2.8 domain, two CIDR α 2.8
55 domains (dark and light pink) interact with each CD36 (blue). **B.** A close up of
56 site 1 with CD36 residue F153 in orange and CIDR α 2.8 residue F660 in green. **C.**
57 A close up of site 2 with CIDR α 2.8 residue D680 in green. **D.** The expression of
58 mutant forms of the CIDR α 2.8 domain with N-linked glycosylation sites
59 introduced in site 1 (F660N:Q662T) and site 2 (D680N:N682T). A small fraction
60 of the site 1 mutant was glycosylated while the majority of the site 2 mutant was
61 glycosylated. **E.** Surface plasmon resonance showing binding of CD36 and CIDR α
62 mutants. Introduction of a partial site 1 glycan and the F153A mutation of CD36
63 both disrupted binding, while a glycan inserted in site 2 did not affect binding.
64 This confirms that site 1 represents the interaction that occurs in solution while
65 site 2 represents a crystal contact.

66

67

68




69

70 **Supplementary Figure 7: Mutagenesis to assess the role of regions of the**
 71 **CIDR α domain in CD36 binding**

72 Surface plasmon resonance analysis of the binding of MCvar1 CIDR α 2.8 to CD36
 73 and the effect of mutations on the interaction. The F660N:Q662T and
 74 D680N:N682T mutants introduce glycosylation sites into potential binding
 75 interfaces. The F153A mutation of CD36 and the F645A and L664 mutations of
 76 MCvar1 CIDR α 2.8 disrupted the hydrophobic core of the binding interface. The
 77 Q643A, D650A and E672A mutations disrupted additional hydrogen bonds
 78 formed between CD36 and MCvar1 CIDR α 2.8. Each set of binding curves shows a
 79 series of two-fold dilutions from a starting concentration of 400nM.

80

81



82


83 **Supplementary Figure 8: Conservation across the CD36-binding CIDRα2-6**
 84 **domains**

85 Sequences of 2386 CIDRα2-6 domains were aligned and a sequence logo
 86 generated of residues equivalent to those found in the MCvar1 CIDRα2.8 domain.
 87 Deletions (><) and insertions (<>) are indicated and underneath the sequence is
 88 a representation of the secondary structure. The green, purple and orange lines
 89 show the positions of disulphide bonds and the stars above the logo denote the
 90 residues that directly interact with CD36.

91

92

93



94


95 **Supplementary Figure 9: Analysis of the binding of CIDR α 2-6 variants to**
 96 **CD36**

97 Surface plasmon analysis of the binding of different CIDR α 2-6 subclasses to
 98 CD36. Each set of binding curves shows a series of two-fold dilutions from a
 99 starting concentration of 400nM.

100

101

102



103

104 **Supplementary Figure 10: The effect of the F153A mutation of CD36 on the**
105 **binding of CIDR α 2-6 variants**

106 Surface plasmon analysis of the binding of equivalent concentrations of different
107 CIDR α 2-6 subclasses to CD36 (black) and the F153A mutant of CD36 (blue). In
108 each case, the concentration of CIDR α domain was 400nM.

109

110

111

112 **Supplementary Table 1:** The interactions between CD36 ectodomain with
 113 CIDR α 2.8
 114

CD36		MCvar1:CIDR α 2.8		Interaction
Residue	Group	Residue	Group	
TYR149	side chain	PRO652	side chain	Hydrophobic
ASN151	side chain NH2	GLN648	side chain CO	Hydrogen bond
ASN151	side chain NH2	ASP650	side chain	Hydrogen bond
GLN152	side chain NH2	ASN583	side chain CO	Hydrogen bond
PHE153	side chain	TRY582	side chain	Hydrophobic
PHE153	side chain	ASN583	back bone	Hydrophobic
PHE153	side chain	PHE586	side chain	Hydrophobic
PHE153	side chain	TRP587	side chain	Hydrophobic
PHE153	side chain	PHE645	side chain	Hydrophobic
PHE153	side chain	PHE660	side chain	Hydrophobic
PHE153	side chain	LEU664	side chain	Hydrophobic
VAL154	side chain	PRO652	side chain	Hydrophobic
VAL154	side chain	PHE660	side chain	Hydrophobic
MET156	side chain	TRP587	side chain	Hydrophobic
MET156	side chain	ILE664	side chain	Hydrophobic
MET156	side chain	ILE673	side chain	Hydrophobic
ILE157	side chain	TRP655	side chain	Hydrophobic
ILE157	side chain	PHE660	side chain	Hydrophobic
ILE157	side chain	THR663	side chain	Hydrophobic
ILE157	side chain	LEU664	side chain	Hydrophobic
ILE157	side chain	LEU669	side chain	Hydrophobic
ASN159	side chain NH2	ASP676	side chain	Hydrogen bond
SER160	side chain	GLU672	side chain	Hydrogen bond
PRO191	backbone O	TRP655	side chain NH	Hydrogen bond
TYR192	side chain	VAL154	side chain	Hydrophobic
TYR192	side chain	TRP655	side chain	Hydrophobic
TYR192	side chain	PRO652	side chain	Hydrophobic
PRO193	side chain	TRP655	back bone	Hydrophobic
PRO193	side chain	ASP654	back bone	Hydrophobic
LYS398	side chain NH3	ASN583	side chain CO	Hydrogen bond
GLN400	side chain NH2	ASP676	side chain	Hydrogen bond

115

116

117

118

119

120 **Supplementary Table 2:** Primers used in cloning

121 Primers for cloning CD36 and MC179var1 CIDR α 2.8:

CD36 ectodomain(35-439)	
Primer 1	ctccaccggtcagaagacaattaaagcaag
Primer 2	gtgggtaccctattagttattttccagttacttgacttc
MCvar1 CIDR α 2.8	
Primer 1	ctccaccggtgaggacaagattatgagctac
Primer 2	gtgggtacc tgggggcatgtgtc

122

123 Primers for mutagenesis:

CD36_F153A	
Primer 1	catatctatcaaaatcaagccgttcaaatgatc
Primer 2	gatcatttgaacggcttgattttgatagatatg
MCvar1 CIDR α 2.8_ F645A	
Primer 1	aagatcaaggaccacgccagaaagcagaaggac
Primer 2	gtccttctgctttctggcgtggctcttgatctt
MCvar1 CIDR α 2.8_ Q648A	
Primer 1	gaccacttcagaaaggccaaggacatccccaag
Primer 2	cttggggatgtccttggccttctgaagtggc
MCvar1 CIDR α 2.8_ D650A	
Primer 1	ttcagaaagcagaaggccatccccaaggactgg
Primer 2	ccagtccttggggatggccttctgctttctgaa
MCvar1 CIDR α 2.8_ L664A	
Primer 1	gactttctgcagaccgccctgatgaaggactg
Primer 2	caggtccttcatcagggcggctgcagaaagtc
MCvar1 CIDR α 2.8_ E672A	
Primer 1	aaggacctgctgctggccatcatccaggacacc
Primer 2	ggtgtcctggatgatggccagcagcaggtcctt
MCvar1 CIDR α 2.8_ F660N:Q662T	
Primer 1	tggaccacgacgacaacctgaccacctgctgatgaag
Primer 2	cttcatcagcaggggtggcaggttgcgtcgtgggtcca
MCvar1 CIDR α 2.8_ D680N:N682T	
Primer 1	caggacacctacggcaacgccaccgagatcaagcggatc
Primer 2	gatccgcttgatctcgggtggcgttgccgtaggtgtcctg

124

125

126

127

128

129

130 **Supplementary Table 3: CIDR domain sequences for recombinant proteins**

131

132 > CIDR α 2.8 MCvar1

133 EDKIMSYNAFFWMVHDMLIDSIKWRDEHGRCINKDKGKTCIKGCNKKCICFQKWVE
134 QKKTIEWGKIKDHFRKQKDI PKDWTHTDDFLQTLMLKDLLLEIIQDTYGDANEIKRIEA
135 LLEQAGVGGIDFAALAGLYTKGFVAEKDTTIDKLLQHEQKEADKCLKTHTDDTCCPPQ
136 EDRSVARS

137

138 >CIDR α 6 IT4var12

139 PWCGLKKQADGTWKRLYENDPQCPIKPKYEPPKGEETPIDVLYTGKENKDIIVKLR
140 EFCKTDGNTGFKNEEWNCYYQVGNDCVLENGEELGGEKKVKDYDNFLMFWVAHMLK
141 DSIEWRSKLSNCLKSDKKTCKKCNDCNCKCYEKWIGKKKVEWTQIKKHFDKQTDFFQG
142 WGRYFVLETVLEGDQFFTDITKAYGDAREIVHIQEMLQKKKEQVLHEDASNMTIID
143 ELLDHELKEAKQCI VNHKDNNC

144

145 >CIDR α 5 IT4var14

146 PWCGLIEEQKDGKWKRI NDHSACKEEELYTPKENAKYTKINVLTSGEGHEDIAKRLKE
147 FCTKTQNGGGSDDCGNSDSSLCEPWQCYQPDQLEKVGGEVDDKLGAGGLCIFEF
148 KMKGEKKVKKQKTFNFFNFVVAHVLDKSIDWRTQLTKLSEDKLKKCEKGCNSNCE
149 CFKKWIEKKEKEWIKVKDQFNKQTD FLEWKHYLVLETILENYFENIQKAYGDLKSI
150 QEMKKMIKENKQKNRRTKDDDEDALDVLFDHEKEEAEDCLDIHE

151

152 >CIDR α 2.2 IT4var24

153 PLCGVNGPKGNWTDIEDKECTLVEKKKYDSNNTTNIDILTADKSQKNILQKYNKFCF
154 NGANDEKSATPTANGGGQIKNWQCYIDESKESGQNNNCILGKWEDFTGNEDVTSYNV
155 FFYNSIIEMLNDSIEWKDKLNICINNKTGKCRKVKCNPCCECYKRWIEKKTELEKIK
156 DHFRKQKDIGDAAQREMTLNI TLNNTFLNDIKDAYPVKQQQLQKIEERLKDQMDFI
157 FERTKTSIDKFLQEEEEQFAEKCI EKHKC

158

159 >CIDR α 2.10 IT4var30

160 PWCGLIEEQKVDGKWKAKNNGECAKVENKIYDPKKTITIEILTGDNEKFGIYEKYNKF
161 CANGKNGVTS GAPDTAPGKNGNQIVTWQCYDKKRSGQNNDCNVEGTWEKFTGKQT
162 VKSYNVFFWDVWYHMLHDSLEWRERLNSCINNAKSQNCNKNKCNRECGCFKAWVVK
163 KDEWDKIKDHFNKQENIGQNVGFIEFNHYGVLEGLDKDELKNIKDTHADAKDIER
164 IDKMLQQAGVVGGRGGENNTIDKFLQEEERFAKDCQQKQEEC

165

166 >CIDR α 2.4 IT4var33

167 PLCGLGMQEPWNPKKDTCEDRGIKTFDDRNPINLLVKDVTGTSIVEKLGGLCG
168 NGAKKNIQTWKCRFESSQNYCVLQNDKKNTPQQEIESFNLSLFWHWIEMLKDSIDW
169 RKEHENCINNNTCKKGCKSKCECFEKWVKRMKEEWKQVLEVYDKQPDFKEVFTPYF
170 TLGYLLKEYFTKIKAPYEEVESVQEFIKEMEQIIDENSNNINATKENNSITKFLQHE
171 EGIATECKKTHNEEK

172

173 >CIDR α 2.9 IT4var45

174 PWCNVNGTKGNWTPKNDDCKPGNEYKNYENTQIPIILTGDKTKSEIVERYRKFCKNN
175 GKNGANGREGGVGGS ENGAASNSDNATTGYCGTNNNDKDP SLCEKWTCYKKEKND
176 GKKAINFVLDKVGKSQEKSMHYNSFFWDVWYHMLHDSLDWRKQLGRCINKKEET
177 KCI GSNKCECFKAWVGHKQEQEWEQIKKHFLKQDDIGQETNCDPMVTLEILLDIDE
178 LLKNIKDTHANADDIDRIQNMLQQAGFDGGVAALVGRCTEGFVAEKDTTIDKFLEKE
179 LQEAEKCLETHKEKC

180

181 >CIDR α 2.7 IT4var61

182 PWCNVKRNNGGWAKASDGECAKEKTKYKKNITEIPVLTDPDEKHNILQKYENFCFN
183 SDGNNGDQIKNWQCYEYEEKDESNDNGDSNICVLQENIGKKEEKSMYPHPPFWKWT
184 EMLIDSMYWRKELKRCINKETKACKNGCKNNDCYKRWVEKKKEWQIKTHFNTQE

185 DMREDIGENTDPGIILAALLNIEDLFENIKDITYGDVKEIKDINQMLEKENEENEGTA
186 GADSKKKNITIDLMINHEQKDAQKCVTNPNPKDC
187
188 >CIDR α 3.2 HB3var13
189 PLCGVKKEKGTWVRKDSMNDCPRIKLYKPINDKVGTPINFLYSGDGQTEIAEKLKKF
190 CRTENSGDSSSARANGASGDKNNGSGSQELYQYWKCQYIGDLQKVREGEDDEDDGQ
191 YDQEVENAGGLCILQKTNGKENVKNQKTSHEIQKTFNPFYFVWVHMLKDSIHWRT
192 KIKSCINNTNELKACKNNKCNDCDCFKRWVKQKQKEWGQIKVHFKTQDIRGKVVN
193 GNTVVSFFLDHDELLEGVLDKGLLLESLQEAYGNAEDIKHIKLLQETDVVGGGEHK
194 TTIDFLLKEELNEAEELKKQKDNK
195
196 >CIDR α 3.5 IT4var15
197 PGCGVELIGNEWKEKNKGECKGGKRYNIPKGTKHNVIPVLSFGDEHKEIEKIEQFC
198 AESNSDSSKLTQWKCYGDKEYEVCTLENRNKSEEDPEEQKTFHNFYFWRHLL
199 NDSIEWRDKINNCIEKAKEGKCKNECKTDCGCFQRWIGKKKEEWGEIKKHFKTQDGF
200 SIFGNNDYFVLENVNLIDELFQDITEAYGNSQKIQGIKDTLAKKKTQAADDATEQKN
201 TIDLLFEYDSEEAECCKKIQEEC
202
203 >CIDR α 2.1 MAL6P1.252
204 PWCQVVKPGPPWKDNDIDSCGKKEISFSDKDTTDDISILSTDRAKKNILQKLENFCRD
205 TEHINHDIWKCHYENTDNDNCILQNTGSEKQKIMPFDAFFLWLTQMLDDSI EWR
206 KKLKTCINNEKPTNCIRGCKKPCFCFERWVEQKEEWEISIEKHFDKQRDI SEEERYI
207 TLEYILNEFFMDKIEKAYGIEKSKELKEKLSNKGHGIIRDTEHSQDAIKILLEHEL
208 EDAKKCTETHNDEKC
209
210 >CIDR α 3.1 DD2var01
211 PYCGVKKVNNGGSSNEWEEKNNGKCKSGKLYEPKPKDKEGTTITITILKSGKGHDDIEEK
212 LNKFCDEKNGDTINSGSGTGGSGGNSGRQELYEEWKCYKGEDVVKVGHDEDDDEED
213 YENVKNAGGLCILKNQKKNKEEGNTSEKEPDEIQKTFNPFYFVVAHMLKDSIHWK
214 KKLQRCLQNGNRIKCGNNKCNNDCECFKRWITQKKDEWGKIVQHFKTQNIKGRGGS
215 NTAELIPFDHDYVLQYNLQEEFLKGDSEDASEEKSENSLDAEEAEELKHLREIIESE
216 DNNQEASVGGGVTEQKNIMDKLLNYEKDEADLCLEIH

217
218
219
220
221
222
223
224